| INTRODUCTION
The development of vulvar squamous cell carcinomas (VSCC) is recognized to be heterogeneous. 1 Approximately 30%-40% of the VSCC are estimated to be attributable to infection with high-risk human papillomavirus (HR-HPV), while in the remaining cases inflammatory conditions like vulvar lichen sclerosus (LS) are risk factors for VSCC development. [2] [3] [4] [5] High-grade vulvar intraepithelial neoplasia (VIN) is considered the precursor lesion of VSCC and can be categorized into HPV-associated usual VIN (uVIN) and HPV-negative differentiated VIN (dVIN). However, in clinical practice, the categorization into uVIN or dVIN is only done in a minority of high-grade VIN and HPV testing is only performed in a minority of VIN. 5 Studies have shown that, in contrast to the majority of VSCC being HPV-negative, the majority of high-grade VIN is HPV-positive. 3, 5 Different factors might explain this paradoxical situation: (1) compared to HPV-positive VIN, HPV-negative VIN is both clinically and histopathologically less likely to be identified, and (2) HPV-negative VIN appears to have a higher cancer progression risk of at least 30%-35% with a shorter time interval between the precancerous VIN phase and invasive cancer. 6, 7 For HPVpositive VIN, the cancer progression risk has been estimated between 3% and 9% in treated patients and about 16% in untreated patients. [7] [8] [9] Given that only a minority of VIN will progress to cancer and most affected women are treated similarly with often mutilating interventions, 10, 11 there is a clinical need for objective biomarkers that can predict the cancer risk in VIN providing opportunities for risk-guided tailored management of women affected with VIN. Molecular markers reflecting genetic and epigenetic host cell alterations associated with vulvar carcinogenesis are expected to be most promising. However, studies on genetic and epigenetic aberrations in VIN and VSCC are limited. 1,2,12-16 TP53 mutations are frequently (~30%) detected in HPV-negative VSCC as well as HPV-negative VIN (~21%), suggesting that TP53 mutations might be involved at an early stage. 1 Immunohistochemically HPV-positive VIN shows usually absence of p53 and strong p16 expression. 2 VSCC exhibit frequent gains of chromosome 3q and 8q, and losses of 3p, 8p, and 11q. 12, 14, [16] [17] [18] [19] [20] [21] To obtain better insight in the molecular events underlying vulvar carcinogenesis, this study was set out to comprehensively analyze HPV-status and DNA copy number alterations (CNA) in a well-characterized series of VIN and VSCC. To allow identification of specific CNA that may reflect the cancer risk for women with VIN, CNA in VIN of women with VSCC were compared with VIN of women without VSCC.
| MATERIALS & METHODS

| Selection of vulvar lesions
Cases of VIN and VSCC were retrieved from the pathology archives of the Departments of Pathology of VU University Medical Center (n = 26), the Academic Medical Center (n = 25) and the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (n = 4), Amsterdam, The Netherlands. VIN adjacent to VSCC was considered to be a surrogate of the most advanced precancerous stage of VIN. Selected cases were enriched with p16 positive cases to achieve comparable group numbers as in regular care only a minority of VSCC cases is p16 (and HPV) positive. Selected cases were reviewed and tissue blocks were selected for sufficient VSCC and adjacent VIN tissue. For the selected VIN cases, long-term pathology follow up data were available from PALGA, the nationwide pathology registry, to evaluate for progression to VSCC. 4 In total, 
| Sequencing analysis
Sequencing results were analyzed as described before. 26 In short, we used the Bioconductor script QDNASeq. 26 Mapping to the human reference genome (GRCh37/hg19) was done using the Burrow's Wheeler Alignmer (BWA). 27 PCR duplicates and reads with a mapping quality lower than 37 were filtered out. Read counts were quantified in nonoverlapping 30 kb windows, followed by a simultaneous loess correction for sequence mappability and GC content. Problematic genome regions were filtered using a blacklist which was based on the 1000 Genome Project and the ENCODE project.
26,28
The X-chromosome was excluded from analysis. Sequencing data was uploaded to ArrayExpress (Annotare; accession number E-MTAB-6113).
| Data processing and clustering
Segmentation (α = .00000000001, number of SD's between means = 2) and subsequent calling of gained, amplified and lost regions was done using CGHcall. Segments with a probability score of ≥0.5 were considered gained, amplified or lost. 29 CGHregions 30 was used to reduce the dimension of the dataset, using thresholds of 0.1 (for CGHtest analysis, see below) or 0.01 (for all other analyses). The use of regions improves the effectiveness of the subsequent statistical analyses and facilitates the interpretation of the results. 30 Unsupervised hierarchical clustering of different subsets of vulvar neoplasms was performed using a modified version of Weighted Clustering of Called Array CGH data (WECCA). 31 The dendrograms were built using total linkage, which resulted in compact, well-separated clusters. 30 The distance between 2 features was defined as the symmetric Kullback-Leibler divergence. 32 
| Statistical analysis
For statistical analysis IBM SPSS Statistics (version 22.0.0.0; IBM, New York, NY, USA) and R (version 3.2.5) were used. The average total number of altered regions was compared between subgroups using the nonparametric Mann-Whitney U test. To compare alterations between subgroups, a chisquare-test was performed using CGHtest, 23 including a permutation-based false discovery rate (FDR) correction for multiple testing. Alterations occurring <5% were a priori excluded and a P-value <.05 with an FDR <0.2 was considered statistically significant. 33 For comparisons between VIN and VSCC, paired cases were excluded from these analyses. Two-sided P-values below .05 were considered statistically significant.
| RESULTS
| HPV-status in vulvar lesions
A series of 65 vulvar lesions, including 24 VSCC and 41 VIN with and without VSCC during follow-up (referred to as VIN VSCC and VIN noVSCC , respectively) were analyzed for HPV-status using p16 
| Frequencies of copy number aberrations
To analyze CNA, all samples were subjected to wholegenome shallow-sequencing. A representative selection of sequencing profiles is provided in Figure 1A- Table 1 ).
To determine the affected chromosomal regions, frequency plots were made of chromosomal gains and losses for each group (Figure 1F-J) . All alterations occurring in at least 33% of each patient group are displayed in Table S1 . Among these, gains were clearly overrepresented.
| Comparison of HPV-positive VSCC with HPV-negative VSCC
From Figure 1F -G it becomes clear that the profiles of HPV-positive and HPV-negative VSCC are overlapping, both having frequent alterations of chromosome 3 and 8. However, the frequencies of these alterations are higher in the HPV-negative VSCC. Almost all HPV-negative VSCC showed chromosome 8 alterations, with gain of chromosome 8q11.21 (including the SNAI2 gene) being detected in 100% of cases. In particular chromosome 3 and 8 isochromosome formation (3p/8p loss simultaneously with 3q/8q gain) was very common in HPV-negative VSCC (54% chromosome 3p loss together with 3q gain, 85% chromosome 8p loss together with 8q gain), but also detected in a subset of HPV-positive VSCC (45% for chromosome 3p loss together with 3q gain, 55% for chromosome 8p loss together with 8q gain). Comparison of HPV-negative and -positive VSCC revealed 4 regions on chromosome 8p, of which 3 consecutive, that were significantly more frequent in HPV-negative VSCC (Table S2) . Additional recurrent alterations in HPV-negative VSCC included gains at, amongst others, 7p, 11q12.3-q14.2, and 14q13.3-q24.1, and losses at 11q14.3-q25 and 17q25.2-q25.3 ( Figure 1F ; Table S1 ). Recurrent alterations in HPV-positive VSCC, although occurring at much lower frequency than for HPVnegative VSCC, comprised gains at 3q, 7q31. Figure 1G ; Table  S1 ). Figure 1H ; Table S1 ). Most of these alterations were also detected in HPV-negative VSCC ( Figure 1F ). Only loss of 1p36.13 was statistically significantly more frequent in HPVnegative VSCC (Table S4 ; excluding paired cases). Figure 1I ; Table  S1 ). Interestingly, none of the HPV-positive VSCC displayed a chromosome 1pq gain or 10q loss. Gains at chromosome 1 in VSCC involved different regions at 1p or 1q, but never gain of 1p and 1q combined. Also chromosome 20 gain, chromosome 4 loss and other frequent alterations were more common in HPV-positive VIN VSCC than in VSCC ( Figure 1G,I ).
|
Gain of 1p34.3-q21.1 was the only significantly differentially altered region between HPV-positive VIN VSCC and VSCC (Table S5 ; excluding paired cases). When comparing paired HPV-positive VIN-VSCC cases, no significantly differently altered regions could be identified. Figure 2B shows the importance scores per chromosomal region, with a higher score indicating a larger contribution of the related alteration to the clustering result. This revealed that gain of chromosome 1pq was the most discriminatory alteration between the clusters, with some additional effect of chromosome 4p and chromosome 20. In line with this observation, especially a gain of 1pq was more frequent in HPV-positive VIN VSCC (81%), compared with VIN noVSCC (21%, P = .001; Figure 2A ). This gain of 1pq was not present in HPV-positive VSCC, even not when the VIN and VSCC part were from the same patient ( Figure S1 ). Figure 1J ; Table S1 ). As described above, most of these were also affected in HPV-positive VIN VSCC , though at different frequencies ( Figure 1I ; Table S1 ). The smallest regions of interest significantly associated with HPV-positive VIN VSCC as compared with VIN noVSCC were gains of 1q21.2-q44 and losses of 11p15.5-p15.3, 11p15.3-p13, and 11q14.1-q21 (Table 2 ).
| Focal copy number alterations in vulvar lesions
Whole-genome shallow sequencing also enabled the detection of focal aberrations, defined as <3 Mb 34 at several genes (Table 3) . Most notably, focal gains and amplifications of the regions encompassing BCL2, CD44 ( Figure S2A ), 11q13/CCND1 ( Figure 1C , Figure S2B ), desmocollins/desmogleins (DSC/DSG; Figure S2C ), JAG1, MET, and TP63 were found (>33% of HPV-positive and/or -negative cases; Table 3 ). We observed that individual samples either displayed many focal alterations or very few, and that, consequently, many genes were co-gained with other genes. Cyclin D1 amplifications were strongly associated with HPV-negative lesions and absent in HPV-positive lesions (P < .001). BCL2 (P = .007) and TP63 (P = .039) gains were more frequent in HPVpositive lesions. Focal deletions were found at RBFOX1/3 and PTPRD, the latter mainly occurring in HPV-negative lesions ( Figure S2D ), an event that has been reported previously.
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| DISCUSSION
Comprehensive chromosomal analysis of vulvar neoplastic lesions showed that HPV-negative and HPV-positive VSCC share many similarities, whereas DNA copy number profiles of VIN are more distinct (schematically presented in Figure 3 ). Most interestingly, the risk of VIN to progress into VSCC seems to be reflected by the extent of chromosomal alterations and specific CNA, in particular a gain of chromosome 1pq for HPV-positive lesions.
Both HPV-negative and HPV-positive VSCC displayed frequent CNA at chromosome 3 and 8, with a highest frequency in HPV-negative VSCC. These alterations are most likely of the isochromosome type since 3p/8p loss almost always occurred concurrently with 3q/8q gain in the same cases. Isochromosome formation of chromosome 8 has been reported previously for VSCC. 21 Also a high frequency of chromosome 3 and 8 alterations in VSCC is in line with previous findings. 14, 17, 18, 20, 21 Allen et al 18 reported that 3q gain and 3p loss are more common in HPV-positive VSCC and 8q gain in HPV-negative VSCC. We found the same for 8q, but did not see major differences for chromosome 3 between HPV-positive and -negative VSCC. Of interest, gains of chromosome 3q26-q28 have been reported to be frequent in both HPV-positive and -negative head and neck squamous cell carcinomas (HNSCC). [35] [36] [37] Among putative target genes on chromosome 8 is the gene SNAI2 (Slug), located on 8q11.21, which was gained in 100% of HPV-negative VSCC. Slug is an epithelial-mesenchymal transition promoting factor reported to be expressed in ~50% of VSCC, and primarily associated with HPV-negative tumors. 38 Loss of chromosome 11q
affected both HPV-positive and -negative VSCC in our study, as was also reported previously. 18, 20 In contrast to the relatively similar CNA patterns in HPVpositive and -negative VSCC, there were striking differences between their precursor lesions, with HPV-negative VIN Both VIN and VSCC displayed several focal alterations of well-known cancer-related genes, including TP63, CD44, cyclin D1, and BCL2. Altered CD44 protein and TP63 mRNA expression in vulvar lesions has been reported by others. [40] [41] [42] [43] Cyclin D1 amplifications were strongly associated with HPV-negative lesions, whereas BCL2 and TP63 were more frequently affected in HPV-positive cases. Gains of TP63 and cyclin D1 have also been described in HNSCC. 35, 36 Cyclin D1 amplification was detected in almost half of HPVnegative VIN and VSCC, compared to 22% of HPV-negative gain, 2 were radically resected indicating that the aggressive treatment might have prevented progression of these lesions into cancer. Of the 11 VIN noVSCC cases without 1pq gain, only 2 were radically resected indicating a low cancer risk in the remaining 9 lesions. Given the relatively low proportion of women with VIN that develop VSCC (ie 3%-16%), many women with HPV-positive VIN presumably have a low cancer-risk profile and will therefore benefit from more conservative, for example, noninvasive management, whereas women with a high cancer-risk profile should be approached more aggressively. Testing for chromosome 1 gain in HPV-positive VIN, for example by fluorescent in situ hybridization, might help to identify VIN at risk for cancer progression and affected women may benefit from a more extensive treatment. While HPV-positive VIN VSCC showed frequent 1pq gain, none of the HPV-negative VIN showed gain of 1p and only 2 cases had gains of 1q. This may implicate a causative role for HPV-infection in the gain of this specific region. Indeed, gains of chromosome 1 are also frequent in HPV-positive anal and cervical intraepithelial neoplasia, and cervical carcinomas. 12, 32, 39, 47 On the other hand, gains of chromosome 1 are infrequent in HPV-positive head and neck squamous cell carcinomas, 32, 35, 37, 48 as was the case for
VSCC. An observation which is not completely understood is that in paired samples of adjacent HPV-positive VIN and VSCC, a gain of 1pq was only detected in the VIN part and not the carcinoma. This might point to a mechanism of tumorigenesis in which 1pq gain enables the progression of VIN, but that upon invasive growth the copy numbers are normalized, potentially relating to intratumor heterogeneity. In addition to chromosome 1pq gain, also losses of 11p15-p13 were significantly associated with VIN VSCC .
Loss of 11p has been previously reported for both vulvar and cervical cancer, 19 as well as anal intraepithelial neoplasia. 39 In conclusion, we demonstrate a considerable heterogeneity of CNA in HPV-positive and -negative VIN lesions, whereas HPV-positive and -negative VSCC show more similar chromosomal profiles. Consistent with their more aggressive clinical course, HPV-negative VIN show similar alterations as VSCC, affecting amongst others chromosome 3, 8, and 11q13.
We found clear differences between HPV-positive VIN VSCC and VIN noVSCC , with both an increased number of CNA and, most importantly, gain of chromosome 1 as a possible indicator of progression risk towards VSCC. These molecular distinctions may provide biomarkers that predict VSCC risk and would fulfill an urgent clinical need to improve current treatment modalities of women affected by VIN. To explore the clinical significance of our findings, further prospective studies are needed.
